Close mobile menu×
Close mobile menu

Suzanne Lentzsch, MD, PhD

Expertise in: 
Medical Oncology, Hematology, Multiple Myeloma, Cancer Care, Amyloidosis
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Clinical Expertise

  • Multiple Myeloma
  • Cancer Care
  • Amyloidosis
  • Medical Oncology
  • Hematology
  • Bone Marrow Transplant
  • MGUS (Monoclonal Gammopathy of Unknown Significance)
  • POEMS Syndrome
  • Peripheral Stem Cell Transplant
  • Waldenstrom's Disease

Education & Training

  • Humboldt University, Faculty of Medicine (Germany)
  • Internship: Humboldt University, Faculty of Medicine (Germany)
  • Residency: Humboldt University, Faculty of Medicine (Germany)
  • Fellowship: Humboldt University, Faculty of Medicine (Germany)
  • Fellowship: Dana Farber Cancer Institute-Harvard Medical School

Honors & Awards

  • 2014 - Leukemia Lymphoma Society, Woman of the year Candidate
  • 2014/15 - MMRF Laugh for Life Honorary Chair
  • 2012 - ASH Advocacy Leadership Institute
  • 2012/13 - “Leukemia Diploma For a selection of worthy articlesin 2012/2013” by Editor in Chief, Leukemia
  • 2012 - Japanese Society of Hematology Appreciation Award
  • 2009 - UPCI Junior Scholar Award in Clinical Cancer Research
  • 2005 - Research Day Awardee, Junior Faculty Category, University of Pittsburgh School of Medicine, Department of Medicine Third Annual Research Day

About Suzanne Lentzsch

Suzanne Lentzsch, M.D., Ph.D. - Director, Myeloma Amyloidosis Service

Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.

Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia.

Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Academic Titles

  • Professor of Medicine

Administrative Positions

  • Director, Multiple Myeloma and Amyloidosis Program

Committee/Societies/Council Memberships

German Society of Cancer
American Society of Hematology
American Association for Cancer Reseach
American Society of Clinical Oncology
International Myeloma Working Group
International Myeloma Society
Herbert Irving Comprehensive Cancer Center in Lymphoid Development and Malignancy
ECOG Auditor
SWOG Study Coordinator
SWOG Myeloma Committee Member
Herbert Irving Comprehensive Cancer Center Protocol Review and Monitoring Committee
  

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Lawrence Hospital

Languages

  • German

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-5098
Fax:
(212) 305-8111
Primary

Research

Dr Lentzsch' translational laboratory research work provided critical insights to understanding of the mechanism of action of thalidomide and IMiDs in multiple myeloma and bone disease. With the goal to bring findings from bench to beside, her current RO1 funded laboratory research investigates the role of metallo-proteinases in multiple myeloma bone disease in order to develop new strategies to target myeloma bone disease.

Dr Lentzsch is leading many phase 1, 2 and 3 clinical trials, including investigator-initiated studies for amyloidosis, newly diagnosed and relapsed/refractory multiple myeloma and for maintenance following transplant for multiple myeloma. She currently focuses on the evaluation of the monoclonal antibody 11-1F4 targeting amyloid directly and thereby inducing the break –up of amyloid. Further Dr. Lentzsch served as national principal investigator in Germany evaluating the role of lenalidomide in the treatment of relapsed Multiple Myeloma and is leading an international multicenter trial to evaluate the role of Xofigo in relapsed refractory multiple myeloma.  As Co-Chair of the Pathways Committee, she played a major role in the development of the Multiple Myeloma Pathways at University Pittsburgh Medical Center.

Her research is funded by various grants and awards from e.g. the NIH, Pennsylvania Department of Health, the German Cancer Foundation, the Leukemia and Lymphoma Society , the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr Lentzsch has published over 70 original articles, editorials, chapters, many as the lead or senior author, in such prestigious journals as Journal of Clinical Investigations, Blood, Cancer Research, and Leukemia.

Grants

PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (P&S Industry Clinical Trial)

Apr 16 2019 - Apr 16 2024

PROSPECTIVE MULTICENTER STUDY TO MEASURE THE IMPACT OF MMPROFILER ON TREATMENT INTENTION IN ACTIVE MULTIPLE MYELOMA PATIENTS. (P&S Industry Clinical Trial)

Sep 20 2017 - Sep 20 2022

A PHASE 1B/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RADIUM-223 DICHLORIDE (BAY 88-8223) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN EARLY RELAPSED MULTIPLE MYELOMA (P&S Industry Clinical Trial)

Mar 13 2017 - Mar 13 2022

CHECKPOINT INHIBITOR PD-1H (VISTA) LINKS MULTIPLE MYELOMA BONE DISEASE AND MYELOMA INDUCED IMMUNOSUPPRESSION (Private)

Jul 1 2019 - Jun 30 2021

TARGETING THE MMP-13/PD-1H AXIS IN MULTIPLE MYELOMA BONE DISEASE (Private)

Jan 3 2019 - Dec 31 2020

PHASE 3 STUDY COMPARING DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (P&S Industry Clinical Trial)

Jan 5 2015 - Jan 5 2020

ROLE OF MMP13 IN MULTIPLE MYELOMA BONE DISEASE (Federal Gov)

Dec 4 2013 - Nov 30 2019

AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF JNJ-54767414 (HUMAX? CD38) (ANTI-CD38 MONOCLONAL ANTIBODY) IN COMBINATION WITH BACKBONE REGIMENS FOR THE TREATMENT OF SUBJECTS WITH MULTIPLE MYELOMA (P&S Industry Clinical Trial)

Apr 23 2014 - Apr 23 2019

PHASE I/II STUDY OF CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (P&S Industry Clinical Trial)

Dec 5 2013 - Dec 5 2018

INHIBITION OF MAP4K2 PATHWAY: A NOVEL AND SELECTIVE THERAPEUTICSTRATEGY AGAINST MULTIPLE MYELOMA (Private)

Dec 1 2017 - Nov 30 2018

A PHASE I DOSE-ESCALATION STUDY OF CARFILZOMIB IN PATIENTS WITH PREVIOULSY-TREATED SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS (P&S Industry Clinical Trial)

Aug 6 2013 - Aug 6 2018

PHASE 1 A/1 B STUDY OF 11-1 F4 MAB FOR THE TREATMENT OF AL AMYLOIDOSIS (Federal Gov)

Sep 10 2015 - Jun 30 2018

EFFECT OF IMID IMMUNOMODULATORY DRUGS ON MEGAKARYOPOIESIS (P&S Industry Clinical Trial)

Jan 14 2013 - Jan 14 2018

RETROSPECTIVE, MULTICENTER, UNCONTROLLED OPEN DIAGNOSTIC STUDY INVOLVING THE RETROSPECTIVE COMPARISON OF THE SENSITIVITY AND SPECIFICITY OF WHOLE BODY LOVE DOSE COMPUTED TOMOGRAPHY AND CONVENTIONAL SK (Private)

Jun 17 2015 - Jun 16 2016

ROLE OF MMP13 IN MULTIPLE MYELOMA BONE DISEASE (Private)

Apr 1 2013 - Mar 31 2014

THE ROLE OF C/EBPBETA AS A POTENTIAL NOVEL TARGET FOR THE TREATMENT OF MULTIPLE MYELOMA (Private)

Mar 1 2012 - Mar 31 2014

EFFECTS OF IMIDS ON GRANULOCYTIC MATURATION (Private)

Mar 1 2012 - Sep 30 2013

EFFECT OF IMMUNOMADODULATORY DERIVATIVES OF THALIDOMIDE AND GRANULOCYTIC MATURATION (Private)

Jun 1 2012 - May 31 2013